+509.2%
GH vs GSK
+53.5%
+455.6%
-45.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.3% | -1.6% | +1.9% | +0.6% |
| 7D | -6.0% | -4.7% | -1.3% | -5.2% |
| 30D | -10.5% | -4.7% | -5.8% | -9.8% |
| 3M | -10.9% | -8.8% | -2.1% | -9.6% |
| 6M | +48.3% | -4.6% | +52.9% | +48.9% |
| YTD | +42.5% | +1.0% | +41.5% | +40.4% |
| 1Y | +46.2% | +6.9% | +39.4% | +42.2% |
| All | +509.2% | +53.5% | +455.6% | +347.3% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling